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ABSTRACT 
Critical quality attribute has been defined as “a physical, chemical, biological or 
microbiological property or characteristic that should be within an appropriate limit, range, or 
distribution to ensure the desired product quality”. Deviations from preset quality metrics may 
potentially result in drug products with inferior therapeutic efficacy and unacceptable clinical 
safety profile. Topical cream formulations may possess numerous quality attributes that can 
affect the permeation of the drug through skin and consequently therapeutic efficacy. CQAs of 
topical formulations are often aimed at characterizing either the physicochemical properties of 
APIs or bulk characteristics of the formulation itself. Solvent systems constitute a major 
proportion of semisolid cream type formulations and its inclusion is critical to overall product 
performance (drug delivery to skin). A majority of the commercially available dermatological 
formulations contain solvent systems (water, ethanol, propylene glycol, glycerol and liquid 
chemical permeation enhancers) but the significance of solvent activity (thermodynamic solvent 
properties) on product performance has not been investigated so far, to be translated into a 
quality metric system (CQA). Water was utilized as a model solvent in order to link 
thermodynamic solvent activity and drug delivery performance of topical semi-solid cream 
systems. The overall aim of the research investigation is to evaluate water activity as a critical 
quality attribute of topical semi-solid dosage forms. Primary goal of this study was to investigate 
the mechanistic effects of water activity on drug release properties of formulation and drug 
permeation across the skin. A related objective was to investigate the mechanistic effects of 
iii 
 
water activity on skin hydration and barrier properties. For mechanistic investigation, a simple 
topical vehicle of varied aw (0.97 - 0.42) was formulated using deionized water with caffeine 
(model drug). Drug transport studies were performed using Franz diffusion cells across cellulose 
and silicone membrane (porous-hydrophilic and non-porous-hydrophobic membrane models, 
respectively) in order to elucidate the effects of water activity on drug release from formulation 
vehicles. Caffeine flux was found to decrease with decreasing water activity of the vehicle. The 
same trend was observed for drug release studies across all synthetic membranes tested. Series of 
dye diffusion study was designed to investigate bulk diffusion/release properties of caffeine 
(model solute) from water activity modulated topical formulations. Sucrose solution was utilized 
as viscosity control to decouple/delineate water activity effects on bulk solute diffusion. Caffeine 
diffusion was relatively slow in low water activity formulation vehicles versus to respective 
viscosity controls of same water activity (sucrose solution). In-vitro permeation studies were 
performed across porcine epidermis to investigate water activity effects on drug permeation 
across model skin membrane. Utilizing drugs of varied skin affinity (caffeine, acyclovir and 
nicotine) IVPT was performed across porcine epidermis under finite and infinite dosing 
conditions. Under both dosing conditions, caffeine, acyclovir and nicotine flux were found to 
reduce with lowering water activity of formulation vehicle. Also, the lag time for drug 
permeation increased with a decrease in water activity of solution formulation. Effects of low 
water activity on skin hydration were studied by placing vehicles of varied water activity on 
porcine skin equilibrated to ambient conditions (22°C/50% RH) and monitoring the changes 
gravimetrically. The hydration level measurement following exposure to different water activity 
formulations showed that the moisture content increases in the epidermis when hydrated with 
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water, as expected. Notably, when exposed to lower water activity solutions, the epidermis 
would lose existing water, exhibiting an apparent dehydration effect. The histological evaluation 
revealed mild perturbation in the stratum corneum layer of the skin samples treated with lower 
water activity vehicles. This was potentially caused by osmotic shrinkage of corneocytes, which 
would be in agreement with the data from the hydration experiment. Role of hydrating agents 
(propylene glycol) on preservation of skin hydration, barrier properties and drug permeation was 
also investigated. Increasing levels of propylene glycol in low water activity vehicle (aw-0.78) 
enhanced drug flux across porcine epidermis. Notably, porcine skin treated with propylene 
glycol-aw 0.78 vehicle mixture (1:1) reverted stratum corneum perturbation caused by low water 
activity vehicle. Manufacturing process studies were undertaken to investigate effects of 
manufacturing process on water activity of topical cream (w/o type). Process parameters had 
profound impact on modulating water activity of a Q1/Q2 similar w/o type cream. Dynamic 
drying measurement revealed same water content in process prototypes. Based upon the results, 
water activity appears to be a potentially critical quality attribute for topical semisolid dosage 
forms, and may have the potential to influence the drug release from formulation as well as the 
permeation of the drug across the skin.  
.  
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CHAPTER 1 
INTRODUCTION 
Topical semi-solid dosage forms are traditionally constituted in the form of creams (oil-
in-water & water-in-oil type based), gels (aqueous & hydro-alcohol based), ointments 
(hydrocarbon & polyethylene glycol based) or pastes
1,2
. Most important advantage of topical 
formulations is the allowance for localized treatment of number of several dermatological 
conditions with minimal systemic exposure. Other relevant advantages include possible 
application of therapeutically relevant higher drug (at the site of action), reduced risk of systemic 
side effects and better patient compliance.  
 Choice of topical semi-solid formulation vehicle depends upon several factors but 
predominantly the type of disease, pathological condition of skin type to be treated and 
biopharmaceutical considerations
3-5
. Generally, lipophilic or hydrocarbon based vehicles are 
employed to treat conditions associated with dry skin. Ointment formulations are very effective 
as they provide moisturizing effect on dry/flaky skin owing to occlusive properties which leads 
to potential hydration of skin and may enhance percutaneous drug absorption. Ointments may 
possess less irritation potential but may have a greasy feel and patients dislike. On contrary, 
emulsion based cream formulations (contain both oil and water) are preferred for their cosmetic 
appeal and may be less viscous and greasy. Depending on the physicochemical properties of 
drug, it is feasible to formulate both hydrophilic and lipophilic drugs (based on the dispersion 
medium: oil or water) to achieve certain degree of solubilization in the dermatological vehicle. 
2 
 
 Topical semi-solid dosage forms may be either simple or complex in nature and may 
contain few or several excipients formulated as a thermodynamically stable/unstable multi-
component system
6
. The components of a topical semi-solid drug product will depend on the 
choice of formulation type and could range from simple solution (containing drug and solvent) to 
inherently complex polymeric gels and thermodynamically unstable emulsion based cream 
systems
7
. A simple topical solution may constitute active pharmaceutical ingredient dissolved in 
suitable solvent together with additives like pH modifiers, co-solvents and preservatives. A 
topical gel formulation may contain viscosity modifiers like cellulose (natural polymer) or 
acrylic (semi-synthetic) polymers in aqueous or hydro-alcohol systems with preferable 
rheological properties for consistent delivery of active ingredients. An ointment may contain 
active ingredients dissolved or dispersed in monolithic hydrocarbon or water washable PEG 
based vehicles. A cream formulation is inherently complex and are predominantly emulsion 
based systems containing two immiscible liquids dispersed (micron scale), one within the other, 
leading to the formation of thermodynamically unstable system (but kinetically stabilized to 
achieve suitable shelf life) with predetermined physical and chemical stability. The stability of 
emulsion can be potentially improved by inclusion of viscosity enhancing agents acting at liquid 
interface. Additional excipients like pH modifiers, humectants, penetration enhancers, drug co-
solvents and preservatives may be employed to arrive at a therapeutically viable dermatological 
base/vehicle for drug delivery.         
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S. No. 
Functional 
Component 
Description Example 
1. 
Ointment 
Base 
Bulking material for semi-solid 
product 
Lanolin, Lanolin 
alcohols, Paraffin, 
Petrolatum, White 
wax, Stearic acid, 
Stearyl alcohol 
2. 
Emulsifying 
Agent 
Surface acting agents to reduce 
interfacial tension and improve 
contact/wetting between hydrophilic 
and hydrophobic medium 
Polysorbate, 
Poloxamer, 
Cetostearyl alcohol, 
Sodium lauryl sulfate 
 
3. Humectant 
Improves retention of water in the 
formulation 
Glycerin, Propylene 
glycol, Polyethylene 
glycol, Sorbitol 
 
4. 
Thickening 
Agent 
Increases viscosity of the formulation 
Bulking material for formulation 
Carbomer (acrylic 
polymers), Cellulose 
polymers, 
Polyethylene oxide, 
Sodium alginate, 
Gelatin 
 
5. Preservative 
Improves microbial stability of the 
product 
Parabens, Benzoic 
acid, Benzalkonium 
chloride, 
Phenoxyethanol 
 
6. 
Permeation 
Enhancer 
Improves percutaneous permeation of 
active ingredients 
Propylene glycol, 
Oleic acid, 
Polyethylene glycol 
 
7. Antioxidant Prevent oxidative degradation 
Butylated 
hydroxytoluene, 
Butylated 
hydroxyanisole 
 
8. 
Acidifying/Al
kalizing 
Agent 
Maintain appropriate pH of the 
formulation 
Citric acid, 
Phosphoric acid, 
Trolamine, Sodium 
hydroxide 
 
9. 
Vehicle/ 
solvent 
Medium for the formulation 
Purified water, 
mineral oil, Propylene 
glycol 
Table 1: Typical Formulation Components of Topical Drug Products 
4 
 
Quality by Design (QbD) in Topical Semi-solid Cream Products 
 Pharmaceutical product quality is instrumental in ensuring patient safety and thus it has 
been realized of late that the quality should be built in the product rather than being finally 
tested. In order to encourage continuous improvement in the pharmaceutical quality control, US 
FDA recently outlined a QbD framework for product development in the ‘Pharmaceutical 
Current Good Manufacturing Practices (cGMPs) for the 21
st
 Century’ initiative to achieve a 
desired state in quality pharmaceutical manufacturing
8
. In conjunction, the International 
Conference on Harmonization (ICH) developed guidelines to globally harmonize technical 
requirements for the manufacture and use of pharmaceutical ingredients and drug products. The 
ICH guidelines have helped to transform the conventional univariate-, trial-and-error based 
product development approach to a multivariate-, science- and risk-based practice governed by 
the principles of Quality by Design (QbD).  
The concepts of QbD are well described in several regulatory guidelines including ‘PAT 
(Process Analytical Technology) – A Framework for Innovative Pharmaceutical Manufacturing 
and Quality Assurance’, ICH Q8 (R2) entitled ‘Pharmaceutical Development’, ICH Q9 entitled 
‘Quality Risk Management’ and ICH Q10 entitled ‘Pharmaceutical Quality System9,10. The ICH 
Q8 guidelines are applicable to Product design, Process design and Scale-up and Transfer while 
ICH Q10 guidelines are relevant from process design through to commercial manufacturing. On 
the other hand, the ICH Q 9 guidelines are known to regulate all the stages of the product life 
cycle. QbD begins with outlining the quality target product profile (QTPP) as well as critical 
quality attributes (CQAs) for the target drug product.  
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QTPP can be defined as “prospective summary of the quality characteristics of a drug 
product that ideally needs be achieved to ensure the desired quality, taking into account safety 
and efficacy of the drug product”.  
Critical quality attribute has been defined as “a physical, chemical, biological or 
microbiological properties or characteristics that should be within an appropriate limit, range, or 
distribution to ensure the desired product quality”. Deviations from preset quality metrics may 
potentially result in drug products with inferior therapeutic efficacy and unacceptable clinical 
safety profile
11
.  
Topical cream products may possess numerous quality attributes that can affect the 
permeation of the drug through skin, skin retention of cream and patient acceptability which can 
further potentially impact therapeutic efficacy and safety
14
.  Few of the critical quality attributes 
are direct result of microstructural arrangement (Q3 characteristics) of the semi-solid cream 
products. Microstructural (Q3) properties of cream products are significantly affected by 
manufacturing process to an extent that even cream lots of Q1/Q2 (qualitative and quantitative) 
similarity result in varying degree of microstructural (Q3) arrangement when processed at 
different conditions. Table 2 contains a comprehensive list of critical quality attributes (inclusive 
of microstructural properties) for a semi-solid cream product.   
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Table 2: Comprehensive list of potential critical quality attributes of a topical semi-solid 
cream product 
1. Organoleptic properties: 
A qualitative description of organoleptic properties of the proposed drug product is 
provided as a test specification which include, color, smell, texture etc. For example, if color of 
the product is critical for patient acceptability and is susceptible to change upon storage, 
adequate quantitative tests should be developed to set the acceptable criteria for the color change.  
2. Drug identification and assay: 
Drug assay affects clinical efficacy of the drug product and the acceptable limits are 
between 90-110%.   
 
List of Critical Quality Attributes of 
Topical Semi-solid Creams 
Organoleptic properties 
Drug identification 
Drug Assay 
Content uniformity/homogeneity 
pH 
Particle size distribution 
Polymorphism 
Globule size distribution 
Rheology 
Water content 
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3. Content uniformity and homogeneity: 
Visual investigation of the drug product may be a useful tool to detect phase separation, 
synersis (extrusion of water from gel) and no foreign matter and product homogeneity. Also, 
drug content uniformity and homogeneity may critically affect the clinical efficacy of the drug 
product and should be assessed using validated analytical techniques. 
4. pH of the formulation: 
pH is a potential critical quality attribute of topical cream formulations. pH may affect 
drug stability and physicochemical properties of semi-solid products like emulsion stability and 
rheological properties. Also, pH affects the product performance by the way of influencing;  
With respect to product performance and therapeutic outcome, solubilized drug content in 
aqueous compartment is the most relevant parameter for emulsion based cream formulations
7
. 
Drugs with pH dependant solubility are greatly affected by pH changes within the formulation. 
Also, it is a well known fact that unionized drug species traverse the stratum corneum barrier 
more effectively compared to the ionized drug species
12
. The ionic equilibrium (ionized-
unionized fraction) of solubilized drug species can also be potentially affected by pH conditions 
built within the formulation.   
Skin membrane acts as a pH dependant perm-selective barrier to permeation of drug 
molecules. It was reported that drug permeability through skin barrier membrane is a function of 
pH of formulation vehicle applied
13
.
 
Inclusion of pH modifiers in formulation has the potential to 
alter baseline pH conditions of the skin membrane therefore eventually altering its permeability 
status. On the other hand, it was reported that the skin membrane was shown to resist 
acid/alkaline regression owing to its buffer capacity and transiently regain its baseline pH
14
. 
Hence, pH appears to be one of the critical quality attribute of topical cream formulation and 
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needs to be controlled after thorough review of the physicochemical properties of drug and its 
permeability characteristics through skin membrane.  
5. Particle size distribution and drug polymorphism: 
If the topical product contains suspended drug particles, then particle size distribution and 
crystal habit of the drug may potentially become critical to intended performance of the 
formulation. Particle size distribution and polymorphic nature may affect drug dissolution rate in 
aqueous component of cream formulation thereby influencing the clinical performance
15
.  
6.  Drug concentration in aqueous phase: 
Drug solubilization in formulation vehicle is one of the prerequisites for percutaneous 
absorption of drugs
15
. Hence, the amount of drug dissolved in the aqueous component of the 
drug product becomes the most relevant parameter to gauge the clinical efficacy
11
.  
7. Globule size distribution: 
In case of emulsion based cream formulations (o/w & w/o type), process parameters 
(homogenization temperature, speed and time) have high impact on globule size distribution of 
dispersed phase and may potentially affect both macro and microstructure level quality attributes 
like organoleptic, sensory, rheological characteristics and drug solubility in formulation vehicle.     
8. Rheology: 
Understanding the rheological properties of topical cream formulations is critical to drug 
delivery across skin, formulation stability and ease of application on skin. Rheological properties 
of semi-solid products are extensively influenced by microstructural (Q3) properties, which may 
be affected by manufacturing process parameters.  Ease of spreading of formulation on skin is 
inversely related to its viscosity and may limit the total area of application thereby limiting the 
area available for percutaneous drug absorption. Also, viscosity inversely affects the rate of drug 
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release from the formulation vehicle, at microstructure level, thereby hindering the rate and 
extent of drug availability for percutaneous absorption.   
9. Specific gravity: 
Specific gravity of cream formulations is very sensitive to manufacturing process due to 
potential for air entrapment in the product. Air entrapment in the product may lead to variation in 
assay value of the product and most importantly the desired dose may not be delivered during 
‘in-use’ conditions. 
 
Problem statement 
Aforementioned critical quality attributes are aimed at characterizing either the 
physicochemical properties of APIs or bulk characteristics of the formulation system itself. 
Solvent systems constitute a major proportion of semisolid cream type formulations and its 
inclusion is critical to overall product performance (drug delivery to skin). A majority of the 
commercially available dermatological formulations contain solvents like water, ethanol, 
propylene glycol, glycerol and liquid chemical permeation enhancers. However, the significance 
of solvent activity (physicochemical properties of solvent) over product performance has not 
been investigated so far to be translated into a quality metric system (CQA).  
Critical quality attribute has been defined as “a physical, chemical, biological or 
microbiological property or characteristic that should be within an appropriate limit, range, or 
distribution to ensure the desired product quality”. Deviations from preset quality metrics may 
potentially result in drug products with inferior therapeutic efficacy and unacceptable clinical 
safety profile. Topical semi-solid cream formulations may possess numerous quality attributes 
that can affect permeation of drug through skin, skin retention of cream and patient acceptability 
10 
 
which can further potentially impact therapeutic efficacy
9
. A comprehensive list of critical 
quality attributes for a topical cream product is given in table 2.  
Aforementioned critical quality attributes are aimed at characterizing either the 
physicochemical properties of API or bulk characteristics of the formulation system itself. 
Solvent systems constitute a major proportion of semisolid cream type formulations and its 
inclusion is critical to overall product performance (drug delivery to skin). A majority of the 
commercially available dermatological formulations contain solvents like water, ethanol, 
propylene glycol, glycerol and liquid chemical permeation enhancers. However, the significance 
of solvent activity (physicochemical properties of solvent) on product performance has not been 
investigated by far in order to construct a quality metric system (CQA).  
Water is the predominantly used solvent type in most cream and hydrogel type semisolid 
formulations (containing as high as 70% w/w and 95% w/w water content, respectively). Hence, 
water was utilized as a model solvent system in the present research work and we propose to 
evaluate water activity as a potential critical quality attribute of topical semi-solid cream 
formulations.  
 
Water Activity 
Water activity (aw) is thermodynamic energy status of solvent water, which is 
mathematically represented as ratio of partial vapor pressure of water (ρ) to vapor pressure of 
pure water (ρo), at equilibrium temperature. Water activity does not essentially depend on 
absolute water content in a system, but is the measure of thermodynamic energy status. Solvent 
water has potential to interact with chemical species like salts, sugars, amino acids, glycols and 
polymers via surface interaction (dipole-dipole), ionic bonds, hydrogen bonds and Van der Walls 
11 
 
forces and as a consequence could alter its thermodynamic activity. Water activity can 
measurably range between 0.0 to 1.0 (pure water)
16
.  
In pharmaceutical applications, water activity has been linked to stability (micro-
biological/physical/chemical), thermodynamic/kinetic activity (drug dissolution) and 
processability (powder flow and compaction) of several pharmaceutical systems. However, it is 
the goal of proposed research study to investigate the effects of water activity of topical 
semisolid formulations on its skin drug delivery attributes. To bridge the knowledge gap, it is the 
objective of the proposed research study to investigate the effects of solvent activity of topical 
semisolid formulations on its performance attributes.  
 
Research Objectives 
Main objective of the research study is to perform mechanistic investigation to outline the 
effects of water activity on individual factors controlling the topical drug delivery (variables 
governing formulation, skin and formulation-skin interface).  
In the first objective, effects of water activity on formulation related variables 
(physicochemical properties) governing topical drug delivery was investigated in detail. 
Utilizing Franz diffusion cells, drug transport studies were performed across synthetic 
membranes (cellulosic and silastic) to evaluate the effects of water activity on in-vitro drug 
release from model topical vehicles of diverse water activity. In addition, physicochemical 
characterization, mathematical modeling and qualitative dye diffusion test were performed to 
mechanistically understand the effects of water activity on drug diffusion/release from water 
activity vehicles.  
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In the second objective, effect of water activity on skin related variables (physiological 
properties) governing topical drug delivery was investigated in details. Utilizing Franz diffusion 
cells, drug transport studies were performed to evaluate the effects of water activity on in-vitro 
drug delivery and drug permeation across model biological membrane (porcine skin). In 
addition, effects of water activity on topical drug delivery under finite/infinite dosing conditions, 
drugs of various physicochemical properties, skin hydrodynamics and barrier properties were 
also investigated. In-vitro permeation studies were undertaken to investigate the role of hydrating 
agents on topical drug delivery upon inclusion in low water activity vehicles. Histological 
investigation was undertaken to study the role of hydrating agents on barrier property restoration 
of porcine skin (model biological membrane).    
In the third objective, model water-in-oil type creams were prepared under various 
process parameters (manufacturing variables) to study its’ effects on resultant water activity of 
the formulation base.  
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CHAPTER 2 
MECHANISTIC INVESTIGATION OF WATER ACTIVITY EFFECTS AT DRUG-
FORMULATION VEHICLE INTERFACE AND INFLUENCE ON DRUG RELEASE  
 
1.  Objective  
Topical drug delivery is a net result of complex interaction between the following: drug-
vehicle interaction, vehicle-skin interaction and drug-skin interaction. In order to investigate the 
effects of water activity at drug-vehicle interface, as well as, to delineate other skin and drug 
related variables, simple aqueous based topical vehicles were prepared using caffeine as a model 
drug. Mechanistic investigation by the way of qualitative dye diffusion test and mathematical 
modeling is undertaken to characterize in-vitro drug release from various water activity vehicles.     
2. Materials 
Caffeine, methylene blue and lithium chloride were purchased from Sigma Aldrich (St. 
Louis, MO). Sucrose NF was purchased from Spectrum chemical manufacturing Co., (New 
Brunswick, NJ). Cuprophan membrane was purchased from Agilent technologies (Santa Clara, 
CA) and silicone membrane was obtained from SMI medical device manufacturer (Saginaw, 
MI). All solutions and dilutions were prepared using purified deionized water (resistivity ≥18.2 
mΩ.cm, Barnstead Nanopure  Diamond TM, Barrington, IL).  
14 
 
3.  Methods 
3.1. Formulation of topical vehicle with modulated water activity (aw) 
To delineate other formulation effects, simple topical solution vehicle was prepared by 
mixing drug in deionized water to yield a homogenous solution. Water activity of topical 
solution vehicle was modified by adding predetermined quantity of lithium chloride to yield a 
wide range of water activity (0.98 - 0.42). Water activity was experimentally determined by dew 
point technique using AquaLab Series 3 (Decagon Devices Inc.). Drug content in topical 
vehicles is maintained as follows (within parentheses is the saturation solubility in water at 25° 
C): caffeine - 15mg/mL (21.6 mg/mL), nicotine – 50 mg/mL (1g/mL) and acyclovir – 1 mg/mL 
(1.6 mg/mL) (KRISTL et al., 1993, Yalkowsky et al., 2010, Budavari and Windholz, 1989). 
3.2. Determination of viscosity of topical drug solution 
Viscosity of all topical solution vehicles were determined using Ostwald viscometer. 
Density of the topical solution vehicles was experimentally determined at 22° C using calibrated 
pipette and weighing balance. Viscosity (0.8990 centipoises) and density (0.9982 g/mL) 
reference values for deionized water (standard reference) at 22° C, was used for the calculation. 
Briefly, time taken for the passage of reference and test solution between the upper and lower 
mark in the viscometer was determined and relative viscosity of the test solution was calculated 
using the formula shown below.  
 
 
   
 
   
          
 
where, Ƞ, ρ and t are viscosity, density and time taken for passage for the standard reference 
(water) and Ƞref, tref and ρref are viscosity, density and time taken for passage for the test solution.  
Stokes-Einstein equation was used to theoretically calculate drug diffusion coefficient as a 
function of vehicle viscosity, 
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where, D is the diffusion coefficient, k is the Boltzmann constant, T is absolute temperature, Ƞ is 
the solution viscosity and r is the hydrodynamic radius of solute/drug. 
3.3. Qualitative dye diffusion test 
Dye diffusion test was performed in control (deionized water, aw-0.98) and test vehicles 
(modulated water activity between aw-0.78 and aw-0.42) using methylene blue as a model solute 
(mol. wt. 319.85 g/mol). Control and test vehicles (3 mL) were taken in scintillation glass vials 
and 50 µL of 0.05% w/v methylene blue solution (prepared in deionized water) was carefully 
added along the side of the vial using a pipette.  As a result, methylene blue solution forms a 
distinct layer or ring on top of the bulk medium (control and test vehicles). Followed by, time 
lapse observation was performed and extent of bulk dye diffusivity was pictorially recorded 
using a digital camera. 
3.4. Analytical methods 
All chemical analysis and drug quantification in transport studies were performed using 
HPLC analytical method. The analytical conditions utilized for all model drugs are as follows. 
Reversed phase chromatography was performed for quantification of model drug caffeine. HPLC 
system consists of Waters
®
 1525 binary pump (Waters
® 
Corporation, Milford, MA) equipped 
with Waters
®
 717 plus autosampler equipped with UV absorbance detector. Chromatographic 
separation was achieved under isocratic mode at a flow rate 1 mL/min on Symmetry
®
 C18 (4.6 x 
150 mm; 5µ) reversed phase analytical column. Caffeine was eluted using mobile phase 
consisting of 50% v/v methanol and 50% v/v water system (50:50 v/v) at analytical wavelength 
254 nm. The chromatogram was analyzed using Breeze
®
 software system.  
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3.5. Statistical treatment 
GraphPad InStat 3 software was used for statistical analysis. One-way ANOVA was used 
to determine the level of significance for correlation between parameters and P < 0.05 was 
considered as the acceptable level of significance.  
4. Results and Discussion  
4.1. Effect of water activity on in vitro drug release from formulation vehicles 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Effect of water activity of the vehicle on caffeine diffusion across Cuprophan 
membrane. Each data point represents mean ± standard deviation (n=6).  
In vitro drug release studies were performed across Cuprophan and silicone membrane to 
systematically evaluate the effects of topical vehicles’ water activity on its drug release 
properties. Synthetic membranes are devoid of heterogeneity and have been extensively used to 
investigate formulation variables and associated drug release phenomena (Houk, 1988).  
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Release studies were performed utilizing Cuprophan membrane (semi-permeable 
hydrophilic porous membrane). In order to avoid differences in transmembrane osmotic pressure 
gradient, receptor compartment was filled with either control or test vehicles with same water 
activity as caffeine solution taken in donor compartment. This precaution was undertaken to 
avoid the osmotic pressure difference across donor and receptor to act as a driving force for drug 
diffusion across Cuprophan membrane.  
In observation, steady state flux of caffeine was found to decrease with reduction in water 
activity of test vehicles. Lowering of solution water activity by one unit (from aw-0.98 to aw-
0.87) resulted in ~3 fold reduction in the steady state flux of caffeine). Further, reduction in 
water activity of control vehicle to aw-0.78, aw-0.54 and aw-0.42, drastically reduced the steady 
state flux by ~11.5, ~38.3 and ~115 fold, respectively. Drug concentration (or chemical 
potential) and diffusivity in formulation vehicle are two major rate controlling factors that 
greatly influence drug release from formulation vehicles (Al-Khamis et al., 1986). Caffeine 
concentration (or drug chemical potential) was found to be very similar in control and all test 
vehicles utilized for drug release studies (table 2)]. However, it is very intriguing that caffeine 
release flux (across Cuprophan membrane) from test vehicle of low water activity (aw-0.78) was 
several fold (12 fold) lower than control vehicle (aw-0.98)Graphical plot figure 1 depicts drug 
release across Cuprophan membrane, from control and test vehicles of different water activity.  
. 
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 Figure 2: Effect of water activity of the vehicle on caffeine permeation flux across silicone 
membrane. Each data point represents mean ± standard deviation (n=6).  
 
Further, release studies were performed across a non-porous hydrophobic membrane 
(silicone membrane) in order to validate the drug release phenomenon observed in case of 
Cuprophan membrane. Here, the rate of transmembrane drug transport was dependant on water 
activity of the vehicle. Although, similar phenomenon was observed in case of release studies 
across Cuprophan membrane, there was a significant difference in the magnitude in the 
amenability. In observation, when water activity of formulation vehicle was lowered, the drug 
diffusion flux across silicone membrane was found to diminish (figure 2). 
Drug diffusivity in a topical vehicle is inversely proportional to medium viscosity (could 
be modeled using Stokes-Einstein equation). An increase in viscosity was observed when water 
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activity of test vehicles was lowered, due to incorporation of lithium chloride (table 3). 
According to Stokes-Einstein equation, diffusion coefficient of caffeine was expected to reduce 
only by a factor of 2 fold, in case of aw-0.78 test vehicle (3.26 x 10
-6 
cm
2
/s) versus control       
(aw-0.98) (7.15 x 10
-6
cm
2
/s). However, from diffusion studies across Cuprophan membrane, a 
resultant 12 fold reductions in caffeine release/diffusive flux was observed for aw-0.78 group 
versus control. Thus, it can be inferred here that lowering water activity of the formulation 
vehicle had profoundly affected the rate of drug release/diffusion from formulation vehicles 
through other mechanisms besides lowering drug diffusion coefficient formulation viscosity 
related effects. 
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4.2. Mathematical Modeling 
 
Table 3: Physicochemical properties of test vehicles of varied water activity  
Each data represents mean ± standard deviation (n=6) 
 
 
 
Water 
activity 
vehicle (aw) 
(22°C) 
 
 
 
Caffeine 
concentration  
 (molar) 
(22°C)  
 
Viscosity  
(centipoises) 
(22°C) 
Theoretical 
modeling (Stokes-
Einstein) of 
caffeine diffusion 
coefficient in water 
activity vehicles 
(cm
2
/s) 
 
Experimental 
determination 
of caffeine 
diffusive flux 
across 
Cuprophan 
membrane 
(mg/0.6 
cm
2
/hour) 
 
0.98 
(control) 
~0.08 0.89 7.15 x 10
-6
 1.15 ± 0.03 
0.87 ~0.08 1.23 5.17 x 10
-6
 0.42 ± 0.08 
0.78 ~0.08 1.95 3.26 x 10
-6
 0.10 ± 0.01 
0.54 ~0.09 2.75 2.13 x 10
-6
 0.02 ± 0.01 
0.42 ~0.10 3.64 1.75 x 10
-6
 0.01 ± 0.001 
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Aforementioned results had invoked extreme curiosity and in order to provide functional 
and more direct evidence, qualitative dye diffusion study was designed to visually characterize 
the influence of water activity on solute diffusivity in water activity vehicles. Methylene blue 
was used as a model dye and a time lapse observation in bulk diffusivity in control, aw-0.78 and    
aw-0.42 vehicles are shown in figure 3a, 3b and 3c. Dye diffusivity in control vehicle (aw-0.98) 
was found to be instantaneous and rapid, yielding a homogenous solution at the end of 2 hours. 
However, in case of aw-0.78 and aw-0.42 test vehicles, rate of dye diffusion was observed to be 
very slow.  
Viscosity of the vehicle medium is expected to slow down solute diffusivity.  From 
Stokes-Einstein relationship, diffusion coefficient of methylene blue would be expected to 
reduce only by 2 fold between control (aw-0.98) and aw-0.78 test vehicle. However, it took longer 
than 12 hours for the dye to diffuse down the medium in aw-0.78 test vehicle but only 2 hours in 
case of aw-0.98 vehicle.  
4.3. Qualitative Dye Diffusion Study 
In conjunction, separate set of dye diffusion studies were performed utilizing sucrose 
solution which acted as viscosity controls for the test vehicles. The latter set of dye diffusion 
studies presumed to be an efficient tool to decouple viscosity related effects from water activity 
in governing the bulk diffusivity of methylene blue. Sucrose solution was prepared at two 
concentration levels 20% and 31% w/v in deionized water to match the viscosity of aw-0.78 and 
aw-0.42 test vehicles, respectively. It was very interesting to observe that methylene blue dye 
took comparatively lesser time for complete diffusion in case of 20% w/v sucrose solution 
(viscosity control) versus aw-0.78 test vehicle. In case of aw-0.78 test vehicle (1.9 cP), it took ~16 
hours (picture not shown) to achieve complete dye diffusion whereas in its viscosity control 
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(sucrose solution – 20% w/v, viscosity - 1.9 cP) complete diffusion was achieved in just ~10 
hours. Similar trend was observed in case of aw-0.42 test vehicle (3.6 cP) and its viscosity 
control. It took ~44 hours for complete dye diffusion in case of aw-0.42 test vehicle (3.6 cP) 
versus ~24 hours for sucrose solution (31% w/v, viscosity - 3.6 cP).  
It was evident that water activity of solution had overwhelming control over solute 
(methylene blue dye) diffusivity compared to viscosity. Owing to relatively low free water 
content in case of aw-0.78 and aw-0.42 test vehicles, methylene blue molecules (methylene blue 
dye) had to endure a more tortuous pathway in order to diffuse through the medium. Hence, the 
bulk diffusion of methylene blue assumed longer time than anticipated (Stokes-Einstein 
equation) in case of low water activity vehicles (aw-0.78 and aw-0.42) compared to respective 
viscosity controls.  
In retrospect, water activity was the predominant reason for anomaly observed in caffeine 
release behavior from various water activity vehicles. Diminishing water activity of formulation 
vehicles had apparent rate-controlling like (non-linear) effects on its drug releasing properties. 
Water activity could be a critical physicochemical property of formulation vehicles that can 
detrimentally affect the drug release characteristics if not controlled appropriately.  
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Figure 3a: Time lapse observation of effect of water activity on solute (methylene blue) 
diffusivity in deionized water (aw-0.98) 
 
Figure 3b: Left: Time lapse observation of effect of water activity on solute (methylene 
blue) diffusivity in formulation vehicle (aw-0.78; viscosity – 1.9cP). Right: Time lapse 
observation of solute diffusion in viscosity control for the aw-0.78 formulation vehicle (20% 
w/v sucrose solution in deionized water, viscosity – 1.9 cP) 
 
Figure 3c: Left: Time lapse observation of effect of water activity on solute (methylene 
blue) diffusivity in formulation vehicle (aw-0.42; viscosity – 3.6 cP). Right: Time lapse 
observation of solute diffusion in viscosity control for the aw-0.78 formulation vehicle (31% 
w/v sucrose solution in deionized water, viscosity – 3.6 cP) 
24 
 
5. Conclusion 
Drug diffusion/release across model synthetic barriers (cellulosic and silastic) from a 
topically applied vehicle was influenced by water activity of the solution. Drug transport studies 
reveal that caffeine diffusive flux is significantly affected by low water activity of formulation 
vehicles. Mathematical modeling suggest that water activity, in addition to viscosity, exerts 
apparent rate controlling properties on drug diffusion within formulation vehicles and 
consequently affecting drug release. Qualitative dye diffusion studies validate that drug diffusion 
is relatively slow in low water activity vehicles and support the findings from drug transport 
study and mathematical modeling.  
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CHAPTER 3 
MECHANISTIC INVESTIGATION OF WATER ACTIVITY EFFECTS AT 
FORMULATION VEHICLE-SKIN INTERFACE AND INFLUENCE ON SKIN DRUG 
DELIVERY 
1. Objective 
In this objective, effects of water activity on topical drug delivery at vehicle-skin 
interface were studied using simple topical vehicles of diverse water activity. Utilizing Franz 
diffusion cells, drug transport studies were performed to evaluate the effects of water activity on 
in-vitro drug delivery and drug permeation using porcine skin model. For a broad spectrum 
investigation of water activity effects at vehicle-skin interface, in-vitro permeation studies were 
performed using model drugs of varied physicochemical properties [log P ranging between (-) 
1.56, (-) 0.79 and 1.17]. In addition, effects of water activity on topical drug delivery under 
finite/infinite dosing conditions, skin hydrodynamics and barrier properties were also 
investigated. Also, in-vitro permeation studies were undertaken to investigate the role of 
hydrating agents on topical drug delivery upon inclusion in low water activity vehicles. 
Histological investigation was undertaken to study the role of hydrating agents on barrier 
property restoration in porcine skin model.    
2. Materials 
Caffeine, nicotine, acyclovir, and sodium fluorescein were purchased from Sigma 
Aldrich (St. Louis, MO). Propylene glycol was acquired from BASF chemical company 
(Tarrytown, NY). Porcine skin was acquired from a local slaughter house and epidermis was 
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harvested using heat separation technique. All solutions and dilutions were prepared using 
purified deionized water (resistivity ≥18.2 mΩ.cm, Barnstead Nanopure  Diamond TM, 
Barrington, IL). 
3. Methods 
3.1. In vitro drug permeation studies across porcine epidermis 
In vitro permeation studies were performed to investigate the effects of water activity of 
topical vehicles on drug permeation across model biological membrane (heat separated porcine 
epidermis). IVPT was performed using vertical Franz diffusion cells and the experimental setup 
remained similar to in vitro release studies involving synthetic membranes. Caffeine (log P: -
0.79; mol. wt.: 194.19 g/mol) was utilized as a model drug and 15 mg/mL drug solution was 
prepared in control (aw-0.98) and test vehicles (aw-0.78). The active diffusion area for drug 
permeation was maintained at 0.64 cm
2
. Permeation studies were performed under both infinite 
and finite dosing conditions. Two hundred microliter and 20 µL of formulation vehicles were 
utilized for infinite and finite dose studies, respectively. 
Utilizing similar experimental conditions, in-vitro permeation studies were also extended for 
model drugs like acyclovir (log P: -1.56; mol. wt.: 225.21 g/mol) and nicotine (log P: 1.17; mol. 
wt.: 162.23 g/mol). Model drugs caffeine, acyclovir and nicotine were chosen based on their 
broad spectrum physicochemical properties. Drug solution was prepared in control (aw-0.98) and 
test water activity vehicles (aw-0.78) and employed for permeation studies at following 
concentration: Nicotine – 50 mg/mL (1g/mL) and acyclovir – 1 mg/mL (1.5 mg/mL).  
 
 
27 
 
3.2.  Effect of varying levels of propylene glycol (humectant) on skin permeation of 
model drug from low water activity vehicle (aw-0.78) 
In vitro permeation testing, under infinite dosing condition, was performed in order to 
investigate the effects of propylene glycol (humectant) on skin permeation of drugs from low 
water activity vehicle (aw-0.78). Porcine epidermis was used a model biological membrane and 
the active diffusion area for drug permeation was maintained at 0.64 cm
2
. Sodium fluorescein is 
utilized as a model drug in this study owing to its analytical sensitivity. Two hundred microliter 
of sodium fluorescein drug solution (1mg/mL) was prepared in aw-0.78 vehicle and added to 
donor compartment which served as control group. Similarly, three different sets of sodium 
fluorescein drug solution (1mg/mL) prepared in aw-0.78 vehicle containing 10, 20 and 30% v/v 
propylene glycol, which served as test group. Water activity was retested for test vehicles after 
inclusion of propylene glycol. Receiver compartment was filled with solution of same water 
activity as the donor (without drug) in order to maintain constant osmotic pressure across donor 
and receiver compartments. At predetermined time points, 0.2 ml samples were withdrawn from 
receiver compartment to analyze the amount of sodium fluorescein permeated across porcine 
epidermis from low water activity vehicles (aw-0.78) containing propylene glycol. 
3.3. Determination of effect of water activity of vehicle on dermal penetration of 
topically applied drugs  
Franz cell setup was utilized to investigate the effect of water activity of topical vehicle 
on dermal penetration of model drug caffeine. Porcine epidermis was utilized as a model 
biological membrane and was sandwiched between donor and receiver compartment in Franz 
diffusion cell apparatus. Donor compartment was filled with 500 µL control and test vehicles 
containing        15 mg/mL caffeine. The receiver compartment was maintained empty. The donor 
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compartment and sampling port of the receiver compartment were covered with paraffin film. 
After 8 hours of treatment, the epidermis was rinsed with deionized water to remove excess drug 
solution off the surface. Followed by, the epidermis was digested in 1N sodium hydroxide 
solution using a tissue homogenizer, solution filtered and drug content analyzed using a suitable 
analytical method. The active diffusion area was maintained at 0.64 cm
2
 and absolute amount of 
caffeine loaded in epidermis was recorded as the extent of dermal penetration of drug.   
3.4.  Determination of skin hydrodynamics  
The effect of water activity of formulation vehicle on skin hydration status was 
determined using porcine epidermis. Porcine epidermis was equilibrated to ambient conditions 
(22° C/60% RH) for 2 hours, as a prerequisite. Followed by, pre-weighed strip of porcine 
epidermis (2 cm x 2 cm) was mounted on Franz diffusion cell apparatus with stratum corneum 
side facing the donor compartment. Donor compartment was filled with test vehicles (aw-0.78 
and aw-0.54) and receiver compartment was kept empty. Donor compartment was then covered 
with paraffin film to prevent water escaping from formulation vehicles. After 6 hours of 
equilibration, epidermis was blotted with Kimwipes
®
 to remove excess solution sticking on the 
skin surface and weighed again. The difference in weight of epidermis pre- and post-treatment 
with test vehicles was recorded as resultant percent water content (test group). In order to 
determine the baseline hydration status (control), pre-weighed epidermis strip (2 cm x 2 cm) was 
equilibrated to ambient conditions (22° C/60% RH) and subsequently stored in hot air oven 
(40°C/25%RH) for an extended period. Followed by, weight of dried epidermis strip was 
determined. Difference in pre-and post-drying weight was recorded as the baseline percent water 
content of porcine epidermis.      
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3.5.  Histology  
Histological investigation was undertaken to investigate the potential structural changes 
in full thickness human cadaver skin following exposure to formulation vehicle of low water 
activity (aw -0.78). A strip of skin (2 x 2 cm) was mounted on Franz diffusion cell apparatus with 
the stratum corneum side facing donor compartment. Topical formulation vehicle of low water 
activity (aw-0.78) was taken in the donor compartment while receiver compartment was 
maintained empty. In addition, low water activity vehicle (aw-0.78) containing propylene glycol 
(1:1) was also investigated as one of the test formulations and deionized water (aw-0.98) served 
as control. Skin was treated with formulation vehicles for a period of 6 hours followed by cross-
sections were prepared for histological investigation. Briefly, skin cross-sections were flash 
frozen in liquid nitrogen and were subjected to freeze drying. Freeze dried skin sections were 
coated with platinum using a sputter coater under argon gas for observation under JSM-7800F 
PRIME field emission scanning electron microscopy (Jeol, Tokyo, Japan).          
3.6. Analytical methods 
All chemical analysis and drug quantification in transport studies were performed using 
HPLC analytical method. The analytical conditions utilized for all model drugs are as follows. 
Reversed phase chromatography was performed for quantification of model drug caffeine. HPLC 
system consists of Waters
®
 1525 binary pump (Waters
® 
Corporation, Milford, MA) equipped 
with Waters
®
 717 plus autosampler equipped with UV absorbance detector. Chromatographic 
separation was achieved under isocratic mode at a flow rate 1 mL/min on Symmetry
®
 C18 (4.6 x 
150 mm; 5µ) reversed phase analytical column. Caffeine was eluted using mobile phase 
consisting of 50% v/v methanol and 50% v/v water system (50:50 v/v) at analytical wavelength 
254 nm. The chromatogram was analyzed using Breeze
®
 software system.  
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3.7. Statistical treatment 
GraphPad InStat 3 software was used for statistical analysis. One-way ANOVA was used 
to determine the level of significance for correlation between parameters and P < 0.05 was 
considered as the acceptable level of significance.  
4. Results and Discussion 
4.1. Effect of water activity of the vehicle on in vitro drug permeation across the porcine 
epidermis 
 
  
 
 
 Porcine epidermis (heat separated) model was utilized to study the effects of topical 
vehicles’ water activity on drug permeation behavior in a biological membrane. Porcine 
epidermis was elected as a model membrane owing to the fact that its stratum corneum lipid 
composition and SC layer thickness closely resembles with that of human skin (Simon and 
Maibach, 2000). Figure 4 represents cumulative caffeine permeation with time under infinite 
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Figure 4: Effect of water activity of the vehicle on caffeine permeation flux across porcine 
epidermis under infinite dosing conditions. Each data point represents mean ± standard 
deviation (n=6) 
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dosing conditions across porcine epidermis. Cumulative permeation of caffeine was found to 
decrease when water activity of formulation vehicle was lowered. The steady state flux of 
caffeine in case of control vehicle was relatively higher than lower water activity vehicles (1.071 
and 0.219 µg/0.6cm
2
/hr for control and aw-0.78 vehicle, respectively. P < 0.05) 
Figure 5: Effect of water activity of the vehicle on caffeine permeation flux across 
porcine epidermis under finite dosing conditions. Each data point represents mean ± 
standard deviation (n=6) 
 
Traditionally, infinite dose technique has been most frequently used to study percutaneous 
absorption events such as drug diffusion properties and penetration enhancement mechanisms. 
During infinite dose studies in vitro, the skin is completely bathed by donor and receptor solution 
and such an incidence is unrealistic under clinical or “in use” conditions. Apparently, transient 
changes in drug concentration are negligible hence changes in permeation profile due to vehicle 
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drying or metamorphosis of the formulation cannot be effectively studied, under infinite dose 
condition.  
Drug permeation behavior under finite dosing technique was reported to closely mimic 
clinical/realistic conditions as the amount of vehicles applied is typically in the range of few 
milligrams per square centimeter of skin. (Franz, 1977, Franz, 1975, Seta et al., 1992, Kubota 
and Yamada, 1990). 
Consequently, in vitro permeation studies were performed under finite dosing conditions as 
well, to ascertain drug permeation behavior from low water activity vehicles, to closely mimic        
“in-use” conditions. Twenty microliter of drug solution (300 µg caffeine content) was utilized 
for finite dose study versus 200 µL (3 mg caffeine content) utilized for infinite dosing. 
Cumulative caffeine flux was found to decrease with lowering water activity of formulation 
vehicles and was found to be at least 3 fold higher for control vehicle versus test vehicle with a 
aw-0.78 (figure 5). In summary, low water activity of topical vehicles conclusively affected drug 
permeation behavior across porcine epidermis, a model biological membrane. 
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Figure 6: Effect of vehicle water activity on acyclovir permeation [log P (-) 1.56] 
across porcine epidermis under infinite dosing conditions. Each data point 
represents mean ± standard deviation (n=6) 
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Figure 7: Effect of vehicle water activity on nicotine permeation [log P 1.17] across 
porcine epidermis under infinite dosing conditions. Each data point represents   
mean ± standard deviation (n=6) 
 
In addition to caffeine (log P: -0.79; mol. wt.: 194.19 g/mol), infinite dose IVPT studies 
were extended for model drugs acyclovir (log P: -1.56; mol. wt.: 225.21 g/mol) and nicotine (log 
P: 1.17; mol. wt.: 162.23 g/mol). In observation, cumulative permeation flux of all model drugs 
from test formulation (aw-0.78) was several folds low (almost infinitesimal) compared with that 
of their respective controls (Figures 6 and 7). It is noteworthy that low water activity of 
formulation vehicle (aw-0.78) had affected permeation of drugs with broad spectrum 
physicochemical properties.  
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4.2. Effect of water activity of the vehicle on skin hydrodynamics  
 
Figure 8 represents the resultant water content in porcine epidermis post 6 hours 
treatment with topical vehicles of varied water activity. The resultant hydration levels (exhibited 
as % values compared to baseline) of porcine epidermis post treatment with control vehicle (aw-
0.98) was found to be 50 ± 3%. Rise in hydration levels here was an expected behavior. 
However, porcine epidermis treated with low water activity vehicle groups (aw-0.78 and aw-0.54) 
lowered the degree of hydration and resulted in < 20% water content (which was lower than the 
baseline values ~37±6%).  
The hydration level measurement following exposure to different water activity 
formulations showed that hydration levels increased when hydrated with water (control vehicle 
aw-0.98), as expected. Notably, when exposed to lower water activity test solutions, epidermis 
would lose baseline water, leading to an apparent dehydration effect. The dehydration 
phenomenon observed here could be attributed to osmotic induced drying effects exerted by low 
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Figure 8: Percent water content in porcine epidermis after treatment with water activity vehicles  
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water activity of formulation vehicles. The extent of skin water loss depends on how low the 
water activity is and water activity gradient established between the outer layer of skin and 
formulation vehicle. 
It was well established that aqueous based solution systems with relatively low water activity 
values exhibits strong osmotic dehydration effects on cellular materials (Gekas et al., 1998, 
Rastogi and Raghavarao, 1994, Toledo, 2007, Sereno et al., 2001). From mathematical equation 
described below, a logarithmic relationship exists between water activity and osmotic pressure 
for aqueous based systems. By virtue, lowering water activity of a system tends to increase its 
osmotic pressure multiple fold.  
            
  
 
      
where,   is the osmotic pressure, R is the gas constant, T is the temperature, Vm molar volume of 
water in the system and aw is the water activity of the system.  
State of hydration of skin is a critical factor which determines the rate of percutaneous 
absorption of drug molecules. Enhanced skin hydration levels typically result in net ‘free’ water 
molecules within the tissue which could act as solvent for predominantly polar permeants. Also, 
free water molecules in the stratum corneum region has potential to alter the permeant solubility 
leading to enhanced partitioning into the skin membrane (Williams and Barry, 2012). Elevated 
hydrating levels of skin was also reported to alter lipid bilayer packing resulting in elevated 
hydrophilic drug fluxes (Alonso et al., 1995, Alonso et al., 1996, Williams and Barry, 2012). 
Increased skin hydration levels have been shown to clearly enhance the skin flux of both 
hydrophilic and lipophilic drug moieties (Idson, 1978, Roberts and Walker, 1993). On contrary, 
osmotic stress induced drying effects were reported to cause structural re-organization of lipid 
37 
 
macromolecular assemblies in the stratum corneum leading to impaired skin permeability 
(Nowacka et al., 2012).  
It was evident that low water activity of formulation vehicles (aw-0.78) exhibited greater 
tendency to induce dehydration in model biological tissue (porcine epidermis) upon topical 
application. A similar dehydrating effect in human skin tissue could be anticipated when topical 
formulations with low water activity were to be utilized for practical drug delivery application. 
Under such circumstances, low water activity of topical vehicles would undoubtedly limit or 
affect skin permeability status or flux of therapeutic agents formulated within.   
4.3. Effect of water activity of the vehicle on dermal penetration of drugs 
 
 
 
 
 
 
 
 
Figure 9:  
 
Figure 9: Effect of water activity of the vehicle on caffeine accumulation in porcine 
epidermis after pretreatment for 8 hours [n=6; *
,
 ** P < 0.001 compared to control 
(aw-0.98)] 
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Most dermatological disorders manifest in the viable epidermis/dermis region hence 
topical dermatological preparations are aimed at delivering therapeutic agents regionally to 
deeper skin layers. This in turn depends on myriad of factors governing nature of drug, 
formulation properties and complex interplay at vehicle-skin interface. Applying this context to 
present investigation, we studied the effect of formulation vehicles’ water activity on skin 
penetration of the model drug caffeine.  
After treating porcine epidermis with control and test formulation vehicles (aw-0.98, aw-
0.78 and aw-0.54) for 8 hours period, epidermis piece was digested in 1N sodium hydroxide to 
determine the absolute amount of caffeine loaded in it. From figure 9, it can be found that 32.76 
± 14.60 µg caffeine was found in epidermis treated with control vehicle whereas, 9.40 ± 7.24 µg 
caffeine was found in epidermis treated with low water activity vehicle (aw-0.78) (P < 0.001 at 
95% confidence interval).  In case of test vehicle aw-0.54 the amount of caffeine loading in 
epidermis was found to be even lower (4.13 ± 1.60 µg) compared to control and aw-0.78 test 
vehicle (P < 0.01).  
The data furnished in figure 7 corroborates that drug penetration in skin (porcine epidermis 
- model biological membrane) is limited by low water activity of test formulation vehicles (aw-
0.78 and aw-0.54). This could be attributed to collective effects of low water activity on (i) drug 
release and diffusivity from formulation vehicle, (ii) limited drug permeation through skin and     
(iii) dehydration effects on skin tissue. In retrospect, water activity of formulation vehicles was 
found to be critical in determining the extent of skin penetration of drugs.  
 
 
 
39 
 
 
 
 
5.4. Histological Evaluation 
 
 
 
 
 
 
 
Figure 10a: Representative SEM picture of human cadaver skin treated with 
control vehicle (aw 0.98) 
 
 
 
 
 
 
 
Figure 10b: Representative SEM picture of human cadaver skin treated with test 
formulation vehicle (aw 0.78) 
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Histological evaluation utilizing scanning electron microscopy was performed to 
investigate water activity led structural changes in the stratum corneum layer in human cadaver 
skin.   Figure 10a and 10b, represents high resolution SEM images obtained for the cadaver skin 
treated with control (aw-0.98) and test water activity vehicle (aw-0.78). Cadaver skin treated with 
control (aw-0.98) served as control for cadaver skin treated with low water activity formulation 
vehicle (aw-0.78).  
The stratum corneum in control skin exhibited tightly bound corneocytes layer with 
minimal or absence of any intercellular space. Opposed to control skin, stratum corneum in 
cadaver skin treated with test vehicle (aw-0.78) was found to exhibit very loosely bound 
corneocytes layer. Moreover, the individual corneocytes layer was observed to remain detached 
from subsequent layers. This trending behavior in SC microstructural modifications was 
attributed to varying degrees of dehydration effects exerted by low water activity of vehicle (aw-
0.78). The drying effects were shown to be associated with significant structural modifications in 
stratum corneum layer sabotaging the transport pathways available for drug permeation through 
skin.  
Thus, low water activity of topical formulation could lead to structural modifications in 
stratum corneum layer and plausibly affect the permeation of topically applied drugs by the way 
of impairing continuous transport pathways available in skin. This was potentially caused by 
osmotic shrinkage of corneocytes, which would be in agreement with the data from skin 
hydrodynamics and skin penetration experiments.  
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4.4. Investigation of propylene glycol (humectants) in enhancing skin permeability of 
drugs from low water activity formulation vehicles and associated effects on skin 
microstructure  
 
 
 
 
 
 
 
 
Figure 11: Effect of propylene glycol on permeation behavior of sodium fluorescein 
from various water activity vehicles (n=6) 
From figure 11, it can be observed that incremental inclusion of small molecule 
humectants, eg. propylene glycol (PG) in low water activity vehicle (aw-0.78) had profound 
effects on enhancing solute permeation across skin. Sodium fluorescein (SF) was utilized as a 
model drug to study the humectants effect owing to its analytical sensitivity. From in vitro 
permeation studies across porcine epidermis, cumulative SF flux from low water activity test 
vehicle (aw-0.78) was found to be negligible (even after prolonged equilibration). Whereas, SF 
flux from control vehicle (aw-0.98) was found to be several folds higher, comparatively. The low 
water activity of test vehicle (aw-0.78) had significantly affected the permeation of sodium 
fluorescein across porcine epidermis and was in good agreement with permeation data obtained 
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for other model drugs (caffeine, acyclovir and nicotine). However, incremental inclusion of 
propylene glycol in the test vehicle (aw-0.78) had led to a dose dependant enhancement in SF 
permeation flux. The trend for SF permeation flux enhancement with propylene glycol dose, 
from low water activity test vehicle (aw-0.78) was as follows: aw-0.78 < aw-0.78 (10% PG) < aw-
0.78 (20% PG) < aw-0.78 (30% PG) < aw-0.98. Utilization of 30% v/v propylene glycol in low 
water activity vehicle (aw-0.78) had enhanced the SF permeation flux to the levels observed in 
case of control vehicle (aw-0.98). This phenomenon could be attributed to the ability of 
humectants to transiently increase skin hydration levels and associated permeability status of 
skin 
On contrary, owing to strong water binding properties, humectants such as propylene 
glycol can be expected to lower water activity of aqueous systems. This was evident in case of 
test formulation (aw-0.78) incorporated with varying levels of propylene glycol. From table 3, it 
can be observed that addition of propylene glycol had further lowered the water activity of test 
formulation vehicle (aw-0.78). In earlier sections, we had demonstrated that relatively low water 
activity of formulation vehicle could diminish drug permeation across skin. However, it was 
interesting that SF flux was found to proportionately increase with propylene glycol levels 
despite a decreasing trend in lowering water activity of the formulation vehicle (aw-0.78).  
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Formulation Vehicle Water activity (aw) 
(22
◦ 
C) 
Control vehicle 0.98 
Test vehicle (aw-0.78) 0.78 
aw-0.78 (10% v/v PG) 0.75 
aw-0.78 (20% v/v PG) 0.73 
aw-0.78 (30% v/v PG) 0.71 
 
Table 4: Effect of propylene glycol levels on water activity of test formulation 
vehicle (aw -0.78) 
Pirot et al., had demonstrated that small molecule humectants (like glycerol and 
propylene glycol) had ability to penetrate into the stratum corneum following topical application. 
The hygroscopic nature of such humectants resulted in efficient binding of water molecules in 
the stratum corneum region and increased its overall water holding capacity (Pirot et al., 2003). 
Nowacka et al. had demonstrated that osmotic drying would cause structural re-organization of 
lipid macromolecular assemblies in the stratum corneum leading to impaired skin permeability.  
However, small molecule humectants (like glycerol and urea) had ability to protect lipid bilayer 
in the stratum corneum against osmotic drying and preserved its fluidity under dry conditions 
(Nowacka et al., 2012).  
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In conjunction, histology studies were undertaken to evaluate the hydrating effects of 
propylene glycol present in low water activity (aw-0.78) vehicle, on structural changes in human 
cadaver skin. Briefly, the cadaver skin was treated with aw-0.78 vehicle containing propylene 
glycol (1:1). Followed by, cross sections of the skin were acquired and observed under SEM to 
evaluate associated structural changes, if any. It can be observed from figure 12 that the stratum 
corneum layers were found to be intact versus skin treated with aw-0.78 (figure 10b). Presence of 
propylene glycol in low water activity vehicle (aw-0.78) could plausibly counteract the 
unfavorable effects of low water activity on skin dehydration and associated structural damage.   
 
Figure 12: Representative SEM picture of human cadaver skin treated with 
propylene glycol and aw-0.78 vehicle (1:1) 
In conclusion, despite the low water activity of topical formulations, inclusion of propylene 
glycol could increase hydration levels in stratum corneum, maintain structural integrity of skin 
and promote drug permeability in skin. 
5. Conclusion 
Drug permeation across the porcine skin from a topically applied vehicle was measurably 
influenced by water activity of topical vehicles. Water activity effects on drug permeation 
(across biological membrane) were found to be universal for drugs of varied skin affinity. 
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Vehicles with low water activity altered the hydrodynamics of skin, and this was associated with 
corresponding impacts on the drug permeation. Inclusion of small molecule humectants like 
propylene glycol, retained skin hydrodynamics and counteracted water activity led effects on 
drug permeation. 
 
 
 
 
46 
 
CHAPTER 4 
INVESTIGATION OF MANUFACTURING PROCESS PARAMETERS ON WATER 
ACITIVITY OF TOPICAL SEMI-SOLID CREAM (WATER-IN-OIL TYPE) 
1. Objective 
Topical cream products may possess numerous quality attributes that can affect the 
permeation of the drug through skin, skin retention of cream and patient acceptability which can 
further potentially impact therapeutic efficacy and safety
38
.  Few of the critical quality attributes 
are direct result of microstructural arrangement (Q3 characteristics) of the semi-solid cream 
products. Microstructural (Q3) properties of cream products are significantly affected by 
manufacturing process to an extent that even cream lots of Q1/Q2 (qualitative and quantitative) 
similarity result in varying degree of microstructural (Q3) arrangement when processed at 
different conditions. In previous chapters, profound investigation was undertaken to elucidate the 
mechanisms through which water activity influence topical drug delivery. In retrospect, water 
activity is a critical microstructural property that plausibly affects drug release and topical drug 
delivery. In the present chapter, focal point is to evaluate if variation in manufacturing process 
conditions could influence resultant water activity of a model semi-solid cream formulation. A 
model water-in-oil type cream formulation iss utilized to study the effects process parameters 
like homogenization speed and time on resultant water activity of topical semi-solid cream. 
2. Materials 
Mineral oil USP, white wax NF, cetostearyl alcohol NF, propylene glycol NF and sodium 
borate NF were purchased from Spectrum chemical manufacturing Co., (New Brunswick, NJ). 
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Cuprophan membrane was purchased from Agilent technologies (Santa Clara, CA) and 
silicone membrane was obtained from SMI medical device manufacturer (Saginaw, MI). All 
solutions and dilutions were prepared using purified deionized water (resistivity ≥18.2 mΩ.cm, 
Barnstead Nanopure  Diamond 
TM
, Barrington, IL). 
3. Methods  
3.1. Preparation of water-in-oil type test cream formulations  
Ingredients 
Quantity 
(% w/w) 
Cetostearyl Alcohol 12.5 
White Wax 12 
Mineral Oil 56 
Sodium Borate 0.5 
Water 19 
Total 100 
Table 5: Composition of model w/o type cream formulation used for manufacturing 
process investigation 
Experimental batches of topical semi-solid cream formulation were prepared in order to 
investigate the effects of processing parameters on modulation of water activity. Two lots (1kg 
batch size) of qualitative and quantitatively similar water in oil type cream formulations were 
prepared by mixing oil phase and water phase (maintained at 70° C) using Silverson
®
 L5M-A 
high shear mixer under varying process conditions (formulation I: mixing at 3500 rpm for 15 
minutes; formulation II: mixing at 7000 rpm for 30 minutes). Mixing process was performed in a 
temperature controlled sealed glass beaker with limited head space in order to avoid loss of water 
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from formulation batches. After high shear mixing phase, both cream lots were allowed to cool 
at a steady rate (5°C/min) until the temperature reaches 45°C while mixing at 1500 rpm then 
stopped. The creams were then allowed to cool to room temperature in a closed jar and post 24 
hour wait period, water content, drying rate (water loss kinetics) and water activity were tested.  
3.2. Determination of water activity of test creams 
Water activity was experimentally determined by dew point technique using AquaLab 
Series 3 (Decagon Devices Inc.). Briefly, a dollop of test cream was placed in sample cup holder 
and introduced into the sample chamber and water activity of the cream was directly read from 
the water activity meter.  
3.3.  Determination of total water content in test creams using thermogravimetry 
Thermogravimetric analysis was performed to determine total water content (post process) 
and rate of water loss for the cream lots using Perkin Elmer
®
 Pyris 1 TGA. To determine total 
water content, samples were loaded in an aluminum sample pan and heated using temperature 
ramp program (5°C/min) from 25°C to  150°C (under constant nitrogen purge) until constant 
weight loss was achieved. The mass loss represents total water content in cream after 
mixing/homogenization unit operation.  
3.4. Determination of drying rate of test creams using thermogravimetry 
To determine drying rate, samples were thermally equilibrated in an aluminum pan under 
constant temperature program (37 ± 1° C) for 24 hours. Drying rate under isothermal 
equilibration determines the water loss kinetics (microstructural differences) between cream 
formulations processed at varying mixing/homogenization conditions. 
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3.5.  Determination of globule size distribution in test creams 
Globule size distribution was determined using optical microscopy technique. 
Approximately, 10 mg cream formulation was directly weighed on a clean glass slide and thin 
film (~10 µm) was formed using film applicator (Gardco
®
 Microm II applicator blade, Japan). 
Samples were viewed under bright field optical microscopy (Axiolab A1, Carl Zeiss, NY) under 
appropriate magnification and images (containing globules) were acquired using AxioVision 
software (Carl Zeiss, NY). Projectile diameter was then analyzed using image analysis suite in 
AxioVision. 
3.6. Statistical treatment 
GraphPad InStat 3 software was used for statistical analysis. One-way ANOVA was used 
to determine the level of significance for correlation between parameters and P < 0.05 was 
considered as the acceptable level of significance.      
4. Results and Discussion 
4.1. Effect of manufacturing process parameters on water activity of test cream 
formulations   
Emulsion based cream formulations are thermodynamically unstable dispersion of two 
immiscible materials (water and hydrocarbons), kinetically stabilized using emulsifier/surfactant 
system. Due to multiple degree of interaction between aqueous–hydrocarbon-emulsifier system, 
cream formulations were hypothesized to encompass intricate polymeric network predominantly 
constructed with partly/completely swollen gel structure (emulsifier phase) containing 
interlamellarly fixed crystalline water (or bound water) and bulk/free water. (Gašperlin et al., 
1994, De Vringer et al., 1987, Junginger, 1984). The concept of bound and free water associated 
with polymeric systems had been around for at least three decades and several researchers had 
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successfully studied the delineated characteristics between bound and free water fraction 
utilizing several thermal techniques (Hatakeyama et al., 1988, Nakamura et al., 1981). Owing to 
the restricted ‘freedom of movement’, bound water exhibits delineated thermodynamic solvent 
properties compared to free/bulk water fraction and such an anomaly in solvent (water) 
properties was reported to affect various phenomena like drug dissolution, dug diffusion, drug 
chemical stability and microbial growth. However, overall thermodynamic energy status of 
bound and free water  can be collectively expressed as water activity (aw) (Caurie, 2011).  
Manufacturing process investigation and material characterization was undertaken in this 
section to understand the influence of process parameters on water activity modulation of certain 
water-in-oil type cream formulation. Table 4, represents the composition of model water-in-oil 
type cream formulation and its process parameters. It can be inferred from table 5 that 
modification of process parameters had significant effects in modulating the water activity of the 
model cream formulation. The cream formulation exhibited a resultant water activity aw-0.93 
when initially processed at relatively lower homogenization speed and time. However, upon 
doubling the homogenization speed and time, the resultant water activity was significantly 
lowered to aw-0.87. Further, thermogravimetric investigation (figure 13) had revealed that 
resultant water content of model creams processed at two difference conditions was almost 
similar (15 – 16 % w/w).  
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Table 6: Effect of process parameters on water activity of w/o type cream 
formulation processed at various conditions 
  
Processing investigation on model cream was performed in a completely sealed glass 
chamber with limited head space. This precaution was necessarily taken to prevent the loss of 
water to ambience during emulsification process. The resultant difference in cream water activity 
between creams processed at two set of conditions can be strictly attributed to difference in 
thermodynamic energy status of water (owing to changes in bound and free water fraction) rather 
than absolute amount of water present in it. It can be inferred here that changes in manufacturing 
process conditions could potentially influence the water activity of semi-solid cream 
formulations and by carefully controlling the process parameters it is feasible to achieve a topical 
cream product with desired water activity.    
 
 
 
Formulation 
Code 
Homogenization 
Speed 
(RPM) 
Homogenization Time 
(minutes) 
Water 
Activity 
( aw) 
22°C 
1. 3500 15 0.932 ± 0.02 
2. 7000 30 0.871 ± 0.03 
52 
 
 
 
 
 
 
 
 
 
 
Figure 13: Determination of total water content in model w/o type cream 
formulation using thermogravimetry 
 
 
 
 
 
 
 
 
 
 
Figure 14: Determination of drying rate of model w/o type cream formulation using 
thermogravimetry 
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Figure 14 represents the drying rate curve of two cream lots possessing significantly 
different water activity as a result of varied process conditions. Evidently, cream lot (formulation 
II) processed at 7000 rpm/30 minutes led to formation of relatively smaller globules (dispersed 
aqueous phase) compared to the cream lot (formulation I) processed at 3500 rpm/15 minutes 
(figure 13).  
 
Figure 15a: Globule size distribution of dispersed phase (aqueous phase) in test 
cream I (aw-0.93) 
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Figure 15b: Globule size distribution of dispersed phase (aqueous phase) in test 
cream I (aw-0.87) 
 
Higher percent of relatively smaller globules in formulation II had plausibly facilitated a 
stronger interfacial interaction leading to an intricate 3D interlamellar gel network containing 
relatively strongly bound water globules. In retrospect, formulation II (processed at 7000 rpm/30 
minutes) was presumed to exhibit relatively higher degree of water binding in interlamellar gel 
network when compared to formulation I (processed at 3500 rpm/15 minutes) and hence these 
differences were found to complement the low water activity of formulation II (aw-0.87) and 
eventually slower drying rate when compared to formulation I (aw-0.93).  
Apparently, under in-use conditions (clinical use), dermatological creams with high water 
activity and higher degree of drying (rate of water loss) could potentially lead to faster 
precipitation of dissolved drug content and thus affect skin permeation of drugs. On contrary, 
dermatological creams with low water activity could strongly retain its water content (otherwise 
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slower rate of water loss) and dissolved drug fraction leading to prolonged skin permeation of 
drugs.  
5. Conclusion 
Variation in manufacturing process conditions influenced water activity of model semi-
solid cream formulations. Net changes in water activity potentially influenced drying rate of the 
cream formulations thereby altering dynamics of topical drug delivery by affecting variables 
governing vehicle-drug and vehicle-skin interactions.  
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